HealthStructural ShiftOct 23, 2026
Clinical trial diversity action plans become mandatory for late-stage studies
FDA guidance on diversity action plans moves toward requirement for Phase 3 trials, reshaping sponsor recruitment strategy.
Regulatory ChangeU.S. Food and Drug Administration
01 · What happened
FDA guidance on diversity action plans moves toward requirement for Phase 3 trials, reshaping sponsor recruitment strategy.
02 · Why it matters
Black Americans have accounted for well under 10% of participants in many FDA-approved drug trials despite higher disease burden in several therapeutic areas.
03 · Actionable implication
Health-tech founders: recruitment, community trust, and decentralized trial infrastructure become sponsor priorities. HBCU medical schools are natural site partners.